bluuebunny/crossref_metadata_2025 huggingface dataset:
Negligible Advantages and Excess Costs of Routine Addition of Breast Ultrasonography to Mammography in Dense Breasts
Authors: Brancato Beniamino , Bonardi Rita , Catarzi Sandra , Iacconi Chiara , Risso Gabriella , Taschini Renzo , Ciatto Stefano
Published: February 2018

Aim

To assess the role of breast ultrasonography as a complement to negative mammography in radiologically dense breasts.

Material and methods

Out of a total series of 49,044 consecutive mammograms reported as negative in asymptomatic women, 25,665 (52.3%) were coded as dense (BI-RADS D3–4) and ultrasonography was recommended. Due to organizational problems, ultrasonography was performed immediately or within 1 month only in 5,227 cases, representing the study series.

Results

Two cancers were detected at immediate ultrasonography (0.03%). The cancer detection rate in women aged 40–49 and 50–69 years was 0.002% and 0.07%, respectively. The benign biopsy rate was 0.5% for core biopsies and 0.02% for surgical biopsies. The cost per ultrasonography-assessed woman was € 56.05, whereas the cost per additional mammographically occult but ultrasonography-detected cancer was € 146,496.53. The mammograms of the 2 cancer cases underwent blind review by an expert reader and were confirmed as negative.

Discussion

Our findings show a low cancer detection rate, substantially lower compared to other clinical studies of ultrasonography in dense breasts, though in accordance with preliminary evidence from an Italian randomized clinical trial within a population-based screening program. The policy of adding ultrasonography to negative mammography in dense breasts seems to have very limited cost-effectiveness, and should not be adopted in routine practice before results of ongoing clinical trials are available.
Factors Affecting Survival in Breast Cancer Patients following Bone Metastasis
Authors: Yavas Ozlem , Hayran Mutlu , Ozisik Yavuz
Published: February 2018

Aims and background

The purpose of the study was to identify prognostic factors that affect survival following bone metastasis in breast cancer patients with first metastases in the skeletal system.

Methods and study design

We analyzed retrospectively the data of 248 metastatic breast cancer patients whose first distant metastasis was in the skeleton.

Results

The median age of the patients at diagnosis was 46 years (range, 23–76). Nearly half of the patients were premenopausal (52.4%). The median disease-free survival was 24 months. For most of the patients (221), bone was the sole first metastatic site, and the disease remained confined to the bone in 99 of them. The remaining patients (n = 27) had both bone and visceral metastasis at the time of first relapse. One hundred and fourteen of the patients (46%) had died by the time of analysis. With the median follow-up of 50.5 months from diagnosis, median survival after bone metastasis was 32 months. In univariate analyses, statistically significant predictors for survival after bone metastasis were axillary lymph node status, T stage of disease, hormone receptor status of the primary tumor, the presence of lymphovascular invasion, involvement of skin, the presence of additional nonosseous metastatic sites at the time of bone relapse, and disease-free interval. In multivariate analyses, the presence of additional non-osseous metastatic sites at the time of bone relapse, T stage of disease, hormone receptor status of the primary tumor, and the presence of lymphovascular invasion were found to be significant independent prognostic factors.

Conclusions

In the result of study, for patients with breast cancer, survival following bone metastasis is affected by secondary prognostic factors such as disease-free interval and extent of metastasis besides primary prognostic factors related to the primary tumor.
Silent Colon Carcinoma Presenting as a Hepatic Abscess
Authors: Giuliani Andrea , Caporale Alessandro , Demoro Martino , Scimò Michele , Galati Francesca , Galati Gaspare
Published: February 2018

Penetration and abscess formation in an adjacent parenchymal organ as presentation of a colon cancer is very uncommon. We report a rare case of pyogenic liver abscess as the first manifestation of an infiltrative and penetrating hepatic flexure colon carcinoma without liver metastases.

A 50-year-old woman was admitted with right abdominal pain, fever and chills. The initial diagnosis was a pyogenic liver abscess. Subsequent CT scan and colonoscopy evidenced a hepatic flexure colon cancer abscessed within segment 6 of the liver. Eight months after a right colectomy and liver resection there was no evidence of disease. The occurrence of a pyogenic liver abscess should raise the suspicion of a silent colon cancer.
Primary Bilateral Adrenal Non-Hodgkin's Burkitt-Like Lymphoma: A Rare Cause of Primary Adrenal Insufficiency. Case Report and Literature Review
Authors: Dobrinja Chiara , Trevisan Giuliano , Liguori Gennaro
Published: February 2018

Aims and background

Primary bilateral adrenal non-Hodgkin's lymphoma is an extremely rare entity. Only 44 cases have been reported in the literature. The most common presenting symptoms are abdominal pain, fever, asthenia, constipation, weight loss or typical symptoms of adrenal insufficiency, hypertension, darkening of skin, orthostatic hypotension or an addisonian crisis.

Methods

The case is presented of a 57-year-old man suffering from primary bilateral adrenal lymphoma with symptoms of adrenal insufficiency syndrome associated with bilateral, stabbing lumbar pain and a palpable mass on the left side. Laboratory tests revealed a considerable increase in lactate dehydrogenase levels, adrenal insufficiency, and high corticotropin levels.

Results

Abdominal CT scan showed two large adrenal masses. A CT-guided fine needle aspiration biopsy revealed a large B-cell non-Hodgkin's lymphoma. Combination chemotherapy according to the CHOP protocol with cyclophosphamide, doxorubicin, vincristine and prednisolone was initiated, which caused a slight reduction in size of the two adrenal masses. The patient underwent a bilateral adrenalectomy with almost complete excision of the tumors. Replacement therapy with cortisone acetate was initiated postoperatively. Adjuvant combination chemotherapy according to the CHOP protocol was started but renal failure gradually emerged and the treatment could not be completed. The patient died seven months after surgery due to acute bronchial pneumonia and progression of disease.

Conclusions

Primary bilateral adrenal non-Hodgkin's lymphoma mainly affects adult men. Diagnosis is based on histological examination. Whether associated or not with radiotherapy, chemotherapy is the most recommended treatment. Surgery, where possible, seems to lead to an increase in survival rates, but it is not possible to draw any definite conclusions on its effectiveness as yet.
Intratumoral Hemorrhage of Mammary Phyllodes Tumor After Menstrual Induction: A Puzzling Presentation
Authors: Sheen-Chen Shyr-Ming , Hsu Wayne , Eng Hock-Liew , Huang Chao-Cheng , Ko Sheung-Fat
Published: February 2018

Background

Mammary phyllodes tumor is an uncommon stromal-epithelial neoplasm with a reported incidence of 0.3% to 0.5% of female breast tumors. Sudden, rapid growth of a mammary phyllodes tumor with intratumoral hemorrhage was noted in a 45-year-old woman after menstrual induction with progesterone and norethindrone acetate. This case is presented here to highlight the possibility of such an onset of phyllodes tumor in order to facilitate its prompt diagnosis.

Case presentation

A 45-year-old woman suffered from missed periods for 2 months and received progesterone for menstrual induction. After treatment, rapid enlargement of her left breast was noted. Tracing the history of the patient, we found that she had already felt an about 3 cm painless lump in her left breast 5 months before this episode. Sonography of the left breast showed a large cystic lesion with some echogenic content and about 150 mL of old blood was obtained by aspiration. Surprisingly, follow-up breast sonography 3 weeks later revealed a large irregular solid mass and a small amount of peripheral cystic content with markedly increased vascularity. Surgery was suggested. A large encapsulated mass consisting of heterogeneous yellow soft tissue and a cystic component measuring 10 × 8 cm was totally excised. Microscopically, the sections revealed branching and cystically dilated glands lined by cuboidal to columnar epithelial cells in a myxoid hypercellular fibroblastic stroma with hyperchromatic nuclei and frequent mitotic figures. The final histological diagnosis was malignant phyllodes tumor.

Conclusion

Progesterone for menstrual induction may cause rapid growth of a phyllodes tumor with resultant internal hemorrhage. Only with the awareness of this entity can a prompt diagnosis be made and optimal treatment be given.
Clinical Report on External Irradiation Combined with Californium-252 Neutron Intraluminal Brachytherapy for Cervical Carcinoma Treatment
Authors: Zhao Huanyu , Wang Keming , Sun Jian , Geng Xin , Zhang Weiming
Published: February 2018

Aims and background

Neutron rays produce high linear energy transfer radiation, which has particular radiobiological characteristics. The aim of the study was to observe the curative effects and complications of external irradiation combined with californium-252 (252Cf) neutron intraluminal brachytherapy for treatment of cervical carcinoma.

Methods and study design

From December 2000 to December 2004, 128 cases of cervical carcinoma staged IIA to IIIB were treated with 252Cf neutron intraluminal brachytherapy using 8–10 Gy-eq per fraction, once a week. The total dose at reference point A was 36–40 Gy-eq in 4 to 5 fractions. From the second day after 252Cf neutron intraluminal brachytherapy, the whole pelvic cavity was treated with 6 MV X-ray external irradiation, applying 2 Gy per fraction 4 times per week. After 20–24 Gy of external irradiation, the center of the whole pelvic field was blocked with a 4-cm-wide lead shield; the total dose of external irradiation was 44–50 Gy.

Results

The short-term curative effects were 95.3% complete remissions and 4.7% partial remissions. The 3-year and 5-year local control rates were 93.5% and 87.9%, respectively. The 3-year and 5-year survival rates were 87.5% and 70%, respectively. The rates of radiation complications were 4.7% for radiation cystitis, 7.8% for radiation proctitis, 6.3% for vaginal contracture and adhesion, and 5.5% for protracted radiation proctitis. The results of univariate and multivariate analysis indicated that differentiation of tumor cells and lymphatic metastasis are the main factors related to the clinical prognosis of cervical carcinoma.

Conclusions

A combination of external irradiation with 252Cf neutron intraluminal brachytherapy for treatment of cervical carcinoma can be well tolerated by patients. The rate of local tumor control is high and radiation complications are few.
Extra Central Nervous System Metastases from Cerebral Glioblastoma Multiforme in Elderly Patients. Clinico-Pathological Remarks on our Series of Seven Cases and Critical Review of the Literature
Authors: Piccirilli Manolo , Brunetto Giacoma Maria Floriana , Rocchi Giovanni , Giangaspero Felice , Salvati Maurizio
Published: February 2018

Aims and background

The aim of the study was to evaluate the treatment of the extracranial metastases from glioblastoma multiforme in the elderly, discussing their uncommon occurrence and their pathogenesis.

Methods

The authors report seven cases of elderly patients (mean age, 69 years), with an initial diagnosis of cerebral glioblastoma multiforme, treated by a grossly total surgical removal and followed by adjuvant radiotherapy (64 Gy in 6 weeks, using Linac) and adjuvant chemotherapy (temozolomide both concomitant and sequential to radiotherapy).

Results

All patients presented a postoperative course characterized by good functional and clinical conditions (Karnofsky performance scale ≥70), which remained unchanged for a mean period of about 21 months (range, 16–23), with no neuroradiological signs of lesion regrowth. After this interval, new clinical signs occurred, and their clinical and radiological investigation showed metastatic repetitions in different sites: lung, liver, humerus and lymph nodes. All the metastases were surgically treated, but regrowth of the brain tumor and progression to deep important neural structures caused the patients’ exitus after a mean interval of about 10 months (range, 8–12) from the diagnosis of metastasis.

Conclusions

We found 128 cases of extra CNS metastases in the English literature. The main features of the patients of the previous reports and of those of the present series were analyzed. The main modalities of glioblastoma multiforme spread, the few theories about the rarity of metastasis, and the probable biological, histological and immunogenetic mechanisms involved in the pathogenesis are described. Although several studies have reported a poor outcome in elderly patients, they affirm that the treatment of those with a Karnofsky performance status >60 should be just as aggressive as in younger patients. This allows them to obtain a longer survival time and to also treat metastases, which are uncommon particularly in the elderly.
Comparison of Endorectal Magnetic Resonance Imaging, Clinical Prognostic Factors and Nomograms in the Local Staging of Prostate Cancer Patients Treated with Radiotherapy
Authors: Cirillo Stefano , Petracchini Massimo , Bona Cristina Maria , Durando Sabina , Ortega Cinzia , Vormola Roberto , Stasi Michele , Malinverni Giuseppe , Aglietta Massimo , Regge Daniele , Gabriele Pietro
Published: February 2018

Aims and background

To determine retrospectively the role of endorectal magnetic resonance in the staging of prostate cancer. The aim of the study was to assess whether it is possible to identify a group of patients with prostate cancer, chosen for certain prognostic factors, eligible for radiotherapy that could take advantage of endorectal magnetic resonance in staging and therapy management.

Methods

Between January 2002 and December 2005, 143 patients with biopsy proven prostate cancer underwent endorectal magnetic resonance. All patients were initially evaluated considering the following prognostic factors: serum prostate-specific antigen at diagnosis, Gleason score, histological grade, involvement of the seminal vesicle and extracapsular extension using the Roach III and ECE equations. The findings were then compared to the results of endorectal magnetic resonance.

Results

The relationship between the variable post-endorectal magnetic resonance stage modification and Gleason score was statistically significant (P = 0.02847). In addition, our study showed a statistically significant correlation between the risk of seminal vesicle involvement according to the Roach III formula and post-endorectal magnetic resonance stage modification (P = 0.01305). Conversely, statistical analysis showed no significant correlation between post-endorectal magnetic resonance stage modification and prostate-specific antigen values (P = 0.83440) or between post-endorectal magnetic resonance stage modification and the risk of extracapsular extension according to the extracapsular extension formula (P = 0.42748).

Conclusions

Our data suggest that endorectal magnetic resonance could be used for staging of the subgroup of patients at high risk of seminal vesicle involvement (>15%). Although we found a statistical correlation between Gleason score and post-endorectal magnetic resonance stage modification, statistical analysis showed no correlation between any of the subgroups. Therefore, it is not possible at the moment to identify a subgroup of patients by Gleason score that may benefit from endorectal magnetic resonance. In our opinion, extracapsular extension values were not useful to select patients for endorectal magnetic resonance.
Myoepithelial Differentiation in Breast Carcinoma
Authors: Kaya Handan , Güllüoğlu Bahadir , Aribal Erkin
Published: February 2018

Background

The aim of presenting this work is to describe a matrix producing carcinoma with anaplastic myoepithelial cell foci, with the coexistence of in situ myoepithelial carcinoma which originated from a sclerosing adenosis.

Case report

A 51-year-old perimenopausal woman presented with a hard irregular lump in her left breast. After histological confirmation of malignancy the patient underwent a modified radical mastectomy. The tumor was composed of a sclerosed fibroadenoma and preexisting sclerosing adenosis with poorly differentiated overt carcinoma within the cartilaginous matrix. There were foci of ordinary intermediate-grade carcinoma in situ and myoepithelial carcinoma in situ.

Results

We performed immunohistochemistry by the streptavidin-biotin horseradish peroxidase method. Estrogen receptor and progesterone receptor were negative, and so was c-erbB-2. Both the invasive and the in situ components were positive for CK7, CK19, CK14, vimentin, smooth muscle actin, nerve growth factor receptor, and epidermal growth factor receptor. By contrast, CK5/6 immunoexpression was found only in the in situ component. Negativity was found for p63 and CD10 within the tumor. While cytoplasmic bcl-2 immunoexpression was detected in some of the tumor cells of the invasive component, intranuclear p53 expression was found to be positive not only in the invasive component but also in the in situ component of the tumor.

Conclusion

The histopathological findings and the immunohistochemistry results support the derivation of the tumor from myoepithelial cells.
CoCanCPG. Coordination of Cancer Clinical Practice in Europe
Authors: Fervers Bèatrice , Remy-Stockinger Magali , Mazeau-Woynar Valèrie , Otter Renèe , Liberati Alessandro , Littlejohns Peter , Qureshi Safia , Vlayen Joan , Characiejus Dainius , Corbacho Belèn , Garner Sarah , Hamza-Mohamed Farida , Hermosilla Teresa , Kersten Sonja , Kulig Michael , Leshem Benny , Levine Nava , Ballini Luciana , Middelton Clifford , Mlika-Cabane Najoua , Paquet Louise , Podmaniczki Erzsèbet , Ramaekers Dirk , Robinson Eliezer , Sanchez Emilia , Philip Thierry
Published: February 2018

All European countries are facing common challenges for delivering appropriate, evidence-based care to patients with cancer. Despite tangible improvements in diagnosis and treatment, marked differences in cancer survival exist throughout Europe. The reliable translation of new research evidence into consistent patient-oriented strategies is a key endeavour to overcome inequalities in healthcare. Clinical-practice guidelines are important tools for improving quality of care by informing professionals and patients about the most appropriate clinical practice. Guideline programmes in different countries use similar strategies to achieve similar goals. This results in unnecessary duplication of effort and inefficient use of resources. While different initiatives at the international level have attempted to improve the quality of guidelines, less investment has been made to overcome existing fragmentation and duplication of effort in cancer guideline development and research. To provide added value to existing initiatives and foster equitable access to evidence-based cancer care in Europe, CoCanCPG will establish cooperation between cancer guideline programmes. CoCanCPG is an ERA-Net coordinated by the French National Cancer Institute with 17 partners from 11 countries. The CoCanCPG partners will achieve their goal through an ambitious, step-wise approach with a long-term perspective, involving: 1. implementing a common framework for sharing knowledge and skills; 2. developing shared activities for guideline development; 3. assembling a critical mass for pertinent research into guideline methods; 4. implementing an appropriate framework for cooperation. Successful development of joint activities involves learning how to adopt common quality standards and how to share responsibilities, while taking into account the cultural and organisational diversity of the participating organisations. Languages barriers and different organisational settings add a level of complexity to setting up transnational collaboration. Through its activities, CoCanCPG will make an important contribution towards better access to evidence-based cancer practices and thus contribute to reducing inequalities and improving care for patients with cancer across Europe.
Nanotechnology: Going Small for a Giant Leap in Cancer Diagnostics and Therapeutics
Authors: Pierotti Marco A , Lombardo Claudio , Rosano Camillo
Published: February 2018

“There is Plenty of Room at the Bottom” - not just “There is Room at the Bottom.” What I have demonstrated is that there is room - that you can decrease the size of things in a practical way. I now want to show that there is plenty of room.

Richard Feynman, December 29, 1959

More than 30 years ago Richard Feynman pointed out that physicists knew no limits to prevent us from doing engineering at the level of atoms. Until recently, though, while the lack of physical limits was accepted as commonplace, molecular engineering was thought of as impractical, unnecessary, or requiring breakthroughs in knowledge and technique that placed it somewhere in the distant future. Many visionaries intimately familiar with the development of silicon technology still forecast it would take between 20 and 50 years before molecular engineering became a reality. This is well beyond the planning horizon of most companies. But recently, everything has begun to change. After the industrial revolution and the “computer age”, are we really facing a new era?
Point-of-Care Systems for Rapid DNA Quantification in Oncology
Authors: Bianchessi Marco , Burgarella Sarah , Cereda Marco
Published: February 2018

The development of new powerful applications and the improvement in fabrication techniques are promising an explosive growth in lab-on-chip use in the upcoming future. As the demand reaches significant levels, the semiconductor industry may enter in the field, bringing its capability to produce complex devices in large volumes, high quality and low cost. The lab-on-chip concept, when applied to medicine, leads to the point-of-care concept, where simple, compact and cheap instruments allow diagnostic assays to be performed quickly by untrained personnel directly at the patient's side. In this paper, some practical and economical considerations are made to support the advantages of point-of-care testing. A series of promising technologies developed by STMicroelectronics on lab-on-chips is also presented, mature enough to enter in the common medical practice. The possible use of these techniques for cancer research, diagnosis and treatment are illustrated together with the benefits offered by their implementation in point-of-care testing.
Use of Nanoparticles for Cerebral Cancer
Authors: Kreuter Jörg , Gelperina Svetlana
Published: February 2018

Nanoparticles made of poly(butyl cyanoacrylate) (PBCA) or poly(lactic-co-glycolic acid) (PLGA) coated with polysorbate 80 or poloxamer 188 enable the transport of cytostatics such as doxorubicin across the blood-brain barrier (BBB). Following intravenous injection to rats bearing intracranially the very aggressive glioblastoma 101/8 these particles loaded with doxorubicin significantly increased the survival times and led to a complete tumor remission in 20–40% of the animals. Moreover, these particles considerably reduced the dose-limiting cardiotoxicity and also the testicular toxicity of this drug. The drug transport across the BBB by nanoparticles appears to be due to a receptor-mediated interaction with the brain capillary endothelial cells, which is facilitated by certain plasma apolipoproteins adsorbed by nanoparticles in the blood.
Assessment of Surgical Treatment in Elderly Patients with Breast Cancer
Authors: De Cesare Alessandro , Burza Antonio , Fiori Enrico , Bononi Marco , Volpino Patrizia , Leone Giovanni , Crocetti Alessandro , Cangemi Vincenzo
Published: February 2018

Aims and Background

The incidence of breast cancer increases with advancing age and in clinical practice approximately 50% of new cases occur in women over the age of 65 years. Although breast cancer in elderly patients presents more favorable biological characteristics than similar-stage cancer in younger women, disease control still remains uncertain and is becoming a major health problem.

Patients and Methods

Between 1984 and 2006, 133 patients aged over 65 with operable breast cancer underwent surgical treatment. Patients with ductal or lobular carcinoma in situ, bilateral breast cancer or a previous malignancy were excluded. The mean age was 72.8 years (range, 66–89). Breast-conserving surgery was performed in patients with early breast cancer (T1, T2 <2.5 cm), while most patients with advanced tumors (T2 >2.5 cm, T3, T4) were treated by modified radical mastectomy.

Results

The pathological stage was I in 44, IIA in 54, IIB in 18, IIIA in 10 and IIIB in 7 patients. Postoperative complications occurred in 13 patients (9%); there were no postoperative deaths. Eighty-nine patients underwent adjuvant therapy (chemotherapy, hormonal therapy). After a median follow-up of 96 months (range, 5–266), disease progression was observed in 21 patients (15.8%). The overall mortality from breast cancer was 11%, whereas the cancer-unrelated mortality was 9%.

Conclusion

There is no evidence that breast cancer has a more favorable prognosis in the elderly and surgical procedures should be carried out as has been established in younger women. At present, elderly patients are much less likely to be entered into randomized clinical trials and are often undertreated. However, in the absence of serious comorbid disease, they are able to withstand standard multimodal treatment options as well as do younger patients.
Stage III-IV Sinonasal and Nasal Cavity Carcinoma Treated with Three-Dimensional Conformal Radiotherapy
Authors: Gabriele Anna Maria , Airoldi Mario , Garzaro Massimiliano , Zeverino Michele , Amerio Simonetta , Condello Cecilia , Trotti Alessandro Boidi
Published: February 2018

Aims and Background

To report the dosimetric data and clinical outcomes of patients with advanced neoplasm of the paranasal sinuses and nasal cavity, treated by three-dimensional conformal radiotherapy.

Methods

Between 2000 and 2005, 31 consecutive patients were treated for locally advanced tumors of paranasal sinuses and nasal cavity. The primary tumor was located as follows: maxillary sinus 15 (48.4%); ethmoid sinus 10 (32.3%); nasal cavity 6 (19.3%). The patients were separated in two groups according to the modality of treatment: group Aincluded 21 patients treated with postoperative three-dimensional conformal radiotherapy with or without chemotherapy; group B included 10 patients treated with radical three-dimensional conformal radiotherapy with or without chemotherapy. The median radiation dose to the planning target volume was 60 Gy (range, 56–63) for patients who underwent complete surgical resection and 68 Gy (range, 64–70) for those who did not have tumor resection or patients with residual disease.

Results

The median follow-up was 42 months. Five-year local tumor control and overall survival actuarial rates were 74% and 72%, respectively, in the postoperative setting, 20% and 25%, respectively, with the primary radiotherapy. Local recurrence was the most common site of failure. No patient developed radio-induced blindness; 4 patients underwent enucleation as part of radical surgery. Dosimetric data are reported.

Conclusions

The local control rate for these tumors remains low. The prognosis depends on localization, tumor stage and treatment modality. Three-dimensional conformal radiotherapy reduces the risk on optical pathways but does not modify outcome.
Are Doses to ICRU Reference Points Valuable for Predicting Late Rectal and Bladder Morbidity after Definitive Radiotherapy in Uterine Cervix Cancer?
Authors: Kim Hak Jae , Kim Suzy , Ha Sung Whan , Wu Hong-Gyun
Published: February 2018

Aims and Background

To evaluate whether doses or dose rates at International Commission on Radiation Units (ICRU) reference points are of value for predicting risks of late rectal and bladder morbidity in patients with uterine cervical cancer who have undergone external beam radiotherapy and intracavitary irradiation.

Methods

Late rectal complications and late bladder complications were evaluated in 54 patients who were treated by external beam radiotherapy followed by intracavitary irradiation between January 1996 and December 1999. External beam radiotherapy was delivered in 1.8 Gy daily fractions to a whole pelvis dose of 50.4 Gy followed by intracavitary irradiation at total point A doses ranging from 75 Gy to 85 Gy. Intracavitary irradiation was performed with dose rates of 0.5–0.7 Gy/h to point A in most patients, but 8 patients were treated at a higher dose rate (0.83–1.15 Gy/h) to shorten the hospitalization period. Biologically effective doses for the reference points were calculated using a linear quadratic model.

Results

Grade 3 rectal and bladder morbidity by Radiation Therapy Oncology Group (RTOG) criteria developed in 4 patients (7.4%) and 1 (1.9%), respectively. An age of >60 years (P = 0.01) and a total dose to the rectal reference point of ≥80 Gy (P = 0.03) were found to be correlated with a higher rate of rectal morbidity. Total dose (≥80 Gy), dose rate (≥0.75 Gy/h), and biologically effective doses (≥135 Gy3) at the bladder reference point were found to be significant factors for the development of late bladder morbidity. By multivariate analysis, age was identified as the only significant factor of late rectal complications, and biologically effective doses at the bladder reference point was the only significant factor of late bladder complications.

Conclusions

RTOG grade 3 late rectal and bladder morbidity developed in respectively 7.4% and 1.9% of the patients. The significant risk factors for late rectal and bladder morbidity were old age and biologically effective doses at the bladder reference point, respectively.
TNM Staging and T-cell Receptor Gamma Expression in Colon Adenocarcinoma. Correlation with Disease Progression?
Authors: Castiglione Francesca , Taddei Antonio , Buccoliero Anna Maria , Garbini Francesca , Gheri Chiara Francesca , Freschi Giancarlo , Bechi Paolo , Degl'Innocenti Duccio Rossi , Taddei Gian Luigi
Published: February 2018

Aims and Background

Colorectal cancer is the second most common cause of cancer-related death in Europe and the United States. Several studies have evaluated the immune response to colorectal cancer, with contradictory results. Some studies showed that lymphocyte infiltration in colorectal cancer seemed to be an important prognostic parameter, a finding not confirmed by other studies. Several studies showed the gamma-delta T-cell receptor repertoire of intestinal adenocarcinoma. In this study, we hypothesize that the presence of T cells with the T-cell receptor gamma complex may play a particular role in carcinogenesis and tumor progression.

Methods

A total of 58 patients with colon adenocarcinoma was included in the analysis. We used the TNM staging system to grade colon cancer.

Results

Thirty samples (52.6%) revealed a polyclonal rearrangement of T-cell receptor gamma. In the N0 cases, only 5 samples revealed a T-cell receptor gamma molecular assessment; in N1/N2 cases, 25 revealed a T-cell receptor gamma molecular assessment.

Conclusions

The results showed statistical significance between the presence of T-cell receptor gamma and N1/N2 stage lymph nodes (P = 0.001).
Gastrointestinal Carcinoid Tumor and Chylous Ascites, a Rare Association with a Poor Prognosis. A Case Report
Authors: Portale Teresa Rosanna , Mosca Francesco , Minona Elisa , Trovato Maria Antonietta , Gangemi Pietro , Bordonaro Roberto , Puleo Stefano
Published: February 2018

Gastrointestinal carcinoid is a rare tumor. The association of this tumor with chylous ascites is uncommon. A review of the English-language literature carried out in 2002 identified only 15 cases. We report a case of chylous ascites, gastrointestinal carcinoid tumor and elevated blood levels of CA-125 in a patient who did not respond to chemotherapy.
Prolonged Survival of a Patient Affected by Pancreatic Adenocarcinoma with Massive Lymphocyte and Dendritic Cell Infiltration after Interleukin-2 Immunotherapy. Report of a Case
Authors: Nobili Cinzia , Degrate Luca , Caprotti Roberto , Franciosi Claudio , Leone Biagio Eugenio , Trezzi Rosangela , Romano Fabrizio , Uggeri Fabio , Uggeri Franco
Published: February 2018

Several studies have shown that there is a paucity of immune cells within the stroma of pancreatic adenocarcinoma, a very aggressive cancer with a median survival of about 18 months. A 65-year-old man presented with jaundice. Abdominal ultrasound revealed intra- and extrahepatic bile duct dilatation and a 45-mm diameter hypoechoic solid mass within the pancreatic head; a computed tomography scan excluded vascular infiltration and metastatic lesions. The patient received immunotherapy consisting of 6,000,000 IU human recombinant interleukin-2 administered subcutaneously twice a day for 3 consecutive days. Thirty-six hours after the last dose, he underwent a pylorus-preserving pancreatoduodenectomy. Because of the presence of high-grade dysplasia detected by intraoperative histological examination of a distal section, a spleen preserving total pancreatectomy was performed. The postoperative course was uneventful. The patient died 32 months after surgery because of local recurrence. Histopathology showed G3 pancreatic ductal adenocarcinoma infiltrating the anterior and posterior peripancreatic tissue, duodenal wall and intrapancreatic common bile duct, with sarcoma-like foci and a component of intraductal tumor involving the common bile duct. In the distal pancreas, widespread foci of pancreatic intraepithelial neoplasia (PanIN2-3) were found. The Ki-67 proliferation index was 16%. TNM staging was pT3 pN1 R1. Sections were immunostained for the T-lymphocyte marker CD3 and for the dendritic cell marker CD1a. Intratumoral infiltration was high for CD1a+ cells and mild for CD3+ cells. Preoperative immunotherapy with interleukin-2 may contribute to massive stromal infiltration of immune cells in pancreatic adenocarcinoma. This may prolong the survival even in the presence of negative prognostic factors (age >65 years, tumor diameter >20 mm, R1, tumor grade G3).
An Adolescent with Rhabdomyosarcoma during Pregnancy
Authors: Meazza Cristina , Casanova Michela , Zaffignani Elena , Clerici Carlo Alfredo , Favini Francesca , Vasquez Roberto , Ferrari Andrea
Published: February 2018

We report the case of a 15-year-old girl with a large gluteal and perineal rhabdomyosarcoma diagnosed at 24 weeks of pregnancy, whose management posed a great clinical dilemma for us. The patient refused to consider a therapeutic abortion, so we opted for a customized treatment with mild doses of chemotherapy administered weekly to control tumor growth while minimizing fetal and perinatal complications. After the delivery of a healthy female, we adopted a more intensive chemotherapy regimen plus irradiation. Despite an initially good response, the disease unfortunately progressed and the patient died of her disease.
Symptomatic Sternal Metastasis Mimicking Cardiac Angina Discovered by Tc-99m Sestamibi Myocardial Perfusion Scintigraphy
Authors: Ceriani Luca , Giovanella Luca
Published: February 2018

Tc-99m sestamibi has been reported to accumulate in several tissues with increased metabolism and particularly in solid tumors. Although the clinical utility of this radiopharmaceutical has been described in primary breast cancer and its axillary involvement, it has not been fully evaluated in local recurrence or distant metastasis. We illustrate the case of a post-mastectomy patient in whom Tc-99m sestamibi single photon emission tomography (SPET) myocardial perfusion scintigraphy, performed to evaluate chest pain mimicking angina, aided in discovering local recurrence of breast cancer in the chest wall. This example underlines that myocardial scintigraphy requires - particularly in a selected group of patients with previous neoplasms of the chest or neck - careful scrutiny for extracardiac uptake and why any unusual or unexpected localization should be pursued and clarified for diagnosis.
Gemcitabine and Cisplatin Treatment of Advanced-Stage Non-Small-Cell Lung Cancer in Patients Given Cisplatin on Day 8
Authors: Akcali Zafer , Calikusu Zuleyha , Sakalli Hakan , Ozyilkan Ozgur
Published: February 2018

Aims and Background

Gemcitabine and cisplatin treatment were administered to patients with advanced-stage, non-small-cell lung cancer. During phase II studies, the treatment is performed using a 28-day cycle, with gemcitabine administered on days 1, 8, and 15. Although it is advised that cisplatin not be administered on the first day, gemcitabine and cisplatin treatment is usually performed using a 21-day cycle, with gemcitabine administered on days 1 and 8, and cisplatin is given on the first day in most phase III studies. In contrast with previous phase III studies, cisplatin was administered on day 8 in our study. Dose density, drug toxicity, and efficacy were analyzed.

Methods and Study Design

Chemonaive patients with stage IIIB or stage IV non-small-cell lung cancer received gemcitabine (1250 mg/m2) on days 1 and 8 plus cisplatin (75 mg/m2) on day 8 every 3 weeks (1 cycle contained 2 applications).

Results

Sixty-seven patients received a total of 293 applications. Dose densities were 92.3% for gemcitabine and 93.9% for cisplatin. The types and rates of grade 3 and grade 4 hematologic toxicities were anemia (6%), granulocytopenia (46%), and thrombocytopenia (6%). Complete remission was seen in 2 patients (3%); partial remission was 40%, stable disease was 39%, and progression of disease, 10%. The median overall survival time was 13 months. The median progression-free survival time was 9.5 months. One-year survival rate was 54% and 2-year survival, 10.4%.

Conclusions

In this 21-day treatment regimen, overall survival was longer than 1 year and the 1-year survival rate was more than 50%. Both the severity and rate of observed thrombocytopenia in the study were very low. Other adverse effects in the current study were comparable to those reported in the literature.
Cell Invasiveness in Sarcomas: A Possibly Useful Clinical Correlation
Authors: Bifulco Katia , De Chiara Annarosaria , Fazioli Flavio , Longanesi-Cattani Immacolata , Cantelmo Anna Rita , Tirino Virginia , Apice Gaetano , Rocco Gaetano , Lombardi Maria Luisa , Carriero Maria Vincenza
Published: February 2018

Aims and Background

The prognosis of each individual patient affected by sarcoma, including those with low histopathologic grading, cannot be reliably predicted at the time of surgery. We have developed an in vitro cell invasion assay on early primary cell cultures derived from surgically removed sarcomas.

Methods

Primary cell cultures were subjected to in vitro cell invasion assays by using Boyden chambers, filters coated with matrigel and fetal bovine serum as a source of chemoattractant. For each primary cell culture, the sarcoma cell invasion index was determined in comparison with the percentage of human fibrosarcoma HT1080 cell invasion extent. The cell invasion index of 7 different sarcomas was evaluated in respect to the outcome of the disease, after a follow-up ranging from 14 to 48 months.

Results

Data evidenced that a low cell invasion index (39.7% ± 8.9) was retained by tumor cells derived from patients with no progression of the disease and with a longer interval of disease-free survival (21 ± 0.8 months). However, an increase in cell invasion index (61% ± 5) was retained by tumor cells derived from patients with progression of the disease and with a shorter disease-free survival (9 ± 3 months). Overall, although only 7 cases were analyzed, a statistically significant correlation was found between disease-free survival and cell invasion index (P = 0.003).

Conclusions

Our data support the possibility that cell invasion assays performed in vitro on cells derived from human sarcomas may be predictive of a more aggressive form of the disease.
Significance of p57Kip2 Down-Regulation in Oncogenesis of Bladder Carcinoma: An Immunohistochemical Study
Authors: Bozdoğan Önder , Atasoy Pinar , Batislam Ertan , Başar M Murad , Başar Halil
Published: February 2018

Aims and Background

Cyclin-dependent kinase inhibitors have important roles in the oncogenesis of various tumors including urothelial cancer. The aim of this study was to establish the importance of p57Kip2, a unique cyclin-dependent kinase inhibitor, in the oncogenesis of bladder carcinoma. This article also focused on another cyclin-dependent kinase inhibitor, p27Kip1, and telomerase enzyme and examined the relationship between these proteins.

Material and Methods

Thirty-one patients with urothelial carcinomas of the bladder and 7 cases with normal urinary bladder mucosa were included in the study. Immunohistochemical study was performed by monoclonal antibodies of p27Kip1, p57Kip2, and the telomerase subunit (hTERT). All immunohistochemical preparations were evaluated by an immunohistochemical histological score.

Results

p57Kip2 and p27Kip1 expression were seen in all of the cases of normal mucosa. In carcinoma cases, 8 of 31 (25.8%) showed p57Kip2 nuclear positivity and 20 of 31 (64.5%) expressed nuclear p27Kip1. HSCOREs of carcinoma cases showed lower scores of nuclear p57Kip2 and p27Kip1 than normal mucosa, but only HSCOREs of nuclear p57Kip2 (P = 0 001) showed statistical significance. Despite unknown significance, cytoplasmic p57Kip2 and p27Kip1 were also evaluated. Immunohistochemical analysis showed that carcinomas expressed higher HSCOREs of hTERT than normal mucosa, and there was a significant difference (P = 0.026) between muscle invasive carcinomas and normal mucosa.

Conclusions

The data showed that p57Kip2 down-regulation along with p27Kip1 is a well-established feature of urothelial carcinoma. Probably, this down-regulation of cyclin-dependent kinase inhibitors supports the proliferation phase of oncogenesis. In the study, we also showed that hTERT expression was up-regulated in higher stages of urothelial carcinoma.
Primary Mucinous Adenocarcinoma of Appendix Treated with Chemotherapy and Radiotherapy: A Case Report
Authors: Topkan Erkan , Polat Yilmaz , Karaoglu Aziz
Published: February 2018

A rare case of primary appendiceal mucinous adenocarcinoma is reported. The presenting signs and symptoms were suggestive of acute appendicitis. An appendectomy was performed resulting in a histological diagnosis of grade 2 mucinous adenocarcinoma of the appendix. The patient was referred to our clinic where he underwent a complementary right hemicolectomy with lymph node dissection. Two of the 17 resected lymph nodes were tumor positive but there was no residual tumor in the hemicolectomy specimen. The patient was staged as T4N1M0 and adjuvant multimodality treatment was planned because he was considered at high risk for local-regional recurrence and distant metastasis. Three cycles of capecitabine 1250 mg/m2 on days 1–14 and oxaliplatin 130 mg/m2 on day 1, every 21 days (CAPOX) were administered, then a total dose of 50.4 Gy external-beam radiation therapy was deliveredtothe primarytumor region and 45 Gy to the lymphatics, and finally3 further cycles of the CAPOX regimen were administered. Multimodality treatment was well tolerated by the patient, who is still alive 25 months after the hemicolectomy procedure with no evidence of disease progression.
An Unusual Presentation of Secondary Involvement of B-Cell Chronic Lymphocytic Leukemia. A Case Report
Authors: Famà Fausto , Barresi Valeria , Giuffrè Giuseppe , Todaro Paolo , Mazzei Sergio , Vindigni Angelo , Gioffrè-Florio Maria
Published: February 2018

Extramammary tumors rarely metastasize to the breast. The commonest tumors to metastasize in breast tissue are lymphoproliferative diseases, melanoma, lung cancer and gynecological malignancies.

Primary breast lymphoma has been reported in the literature with a maximum percentage of about 0.5% of all breast malignancies, while secondary localizations of lymphomas in the breast are less well studied in the literature than primary ones. The authors report a rare case of a secondary localization of B-cell chronic lymphocytic leukemia to the breast in which the diagnosis was obtained by histopathology and immunohistochemistry and further confirmed by molecular data.

This occurrence must be considered in the differential diagnosis of a breast lump so that the primary hematological disease can be adequately treated and the correct type of breast surgery performed.
Insight into long-term histological, proliferative and apoptotic modifications in ileal orthotopic neobladder and conduit mucosa
Authors: Dellis Athanasios E , Demonakou Maria , Papatsoris Athanasios G , Chrisofos Michail , Bamias Aris , Deliveliotis Charalambos
Published: February 2018

Aims and background

To assess the long-term histological, apoptotic and proliferating alterations of the intestinal mucosa of ileal conduits and orthotopic neobladders.

Methods

Fifty patients (46 males, 4 females), aged 52–78 years, who underwent urinary diversion with either ileal orthotopic neobladder (group ON, 20 patients) or conduit (group IC, 30 patients) from 2001 to 2005, were included in this prospective study Ileal samples were collected during surgery (controls) and by random mucosal biopsies 6, 12, 24, 36 and 48 months later. Histological (villi height, crypt depth, eosinophil cell count), proliferation (Ki67 immunochemistry), and apoptotic (Bcl-2 immunochemistry TUNEL) parameters were assessed.

Results

During the 4-year follow-up, we recorded progressive villi area, height and crypt depth reduction, mucosa flattening, and inflammatory and eosinophilic infiltration. Villi height: crypt depth ratio showed a statistically significant difference ( P <0.05) between the two groups from the 6th month. Dysplasia, metaplasia, and neoplasia were not observed. Bcl-2 values showed a progressive increase until 24 months in group ON and 12 months in group IC, followed by a decline thereafter. Ki-67 values showed a progressive increase after 6 months in group ON and an increase until 24 months followed by a decline thereafter in group IC. TUNEL showed two peaks, at 24 and 48 months.

Conclusions

Histological adaptation was revealed in both groups, with statistically significant differences in favor of orthotopic substitution. Proliferative and apoptotic pathways are implicated as demonstrated by relevant modifications of Bcl-2, Ki-67 and TUNEL, in accord with the histological adaptation.
Lymph Node Metastases of Merkel Cell Carcinoma from Unknown Primary Site: Report of Three Cases
Authors: De Cicco Luigi , Vavassori Andrea , Jereczek-Fossa Barbara A , Pruneri Giancarlo , Catalano Gianpiero , Ferrari Anna Maria , Orecchia Roberto
Published: February 2018

Merkel cell carcinoma (MCC) is an uncommon aggressive neuroendocrine skin carcinoma. It usually affects sun-exposed skin of white elderly people. MCC is characterized by a high incidence of early locoregional relapse and distant metastases. Because of its rarity and the resulting lack of prospective randomized trials, data regarding the optimal treatment of MCC are limited. Despite aggressive multimodality treatment, the prognosis of patients bearing MCC is often poor. We report three cases of lymph node metastases of MCC with unknown primary sites. Two patients died 17 and 28 months after diagnosis due to brain and pancreatic metastases, respectively, without evidence of cutaneous disease. The third patient is alive and free of tumor at 16 months from the diagnosis. After an accurate diagnosis of lymph node metastases from MCC, the absence of a primary tumor at complete initial evaluation and during adequate follow-up can confirm this particular clinical scenario. The prognosis seems to be analogous to that of cases with similar disease stage (lymph node involvement) but a known primary site.